The therapy, dubbed IGV-001, involves patients' own glioblastoma cells mixed with an antisense drug and implanted into the abdomen in dime-sized plastic chambers.
AstraZeneca, Daiichi Sankyo to Discuss Pan-Cancer Enhertu Activity With Regulators
The drugmakers announced that their antibody-drug conjugate met its prespecified objective response rate target in a Phase II trial involving patients with different HER2-expressing tumors.
FDA Expert Committee Favors GSK's Jemperli Study Plan as Curative-Intent Rectal Cancer Treatment
The agency also converted a previous accelerated approval into a full approval for the immunotherapy in mismatch repair-deficient endometrial cancer.
FDA Places Partial Clinical Hold on Phase I Trial of Blueprint's CDK2 Inhibitor
The company will not enroll any new patients in the VELA trial while it investigates incidents of visual adverse events in some patients who received BLU-222.
Foundation Medicine, Karyopharm Therapeutics Partnering on Endometrial Cancer CDx
The test would help identify patients who have advanced or recurrent TP53 wild-type endometrial cancer and could benefit from the experimental drug Xpovio.